Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses

BACKGROUND: Though currently approved immunotherapies, including chimeric antigen receptor T cells and checkpoint blockade antibodies, have been successfully used to treat hematological and some solid tumor cancers, many solid tumors remain resistant to these modes of treatment. In solid tumors, the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Brempelis, Katherine J, Cowan, Courtney M, Kreuser, Shannon A, Labadie, Kevin P, Prieskorn, Brooke M, Lieberman, Nicole A P, Ene, Chibawanye I, Moyes, Kara W, Chinn, Harrison, DeGolier, Kole R, Matsumoto, Lisa R, Daniel, Sara K, Yokoyama, Jason K, Davis, Amira D, Hoglund, Virginia J, Smythe, Kimberly S, Balcaitis, Stephanie D, Jensen, Michael C, Ellenbogen, Richard G, Campbell, Jean S, Pierce, Robert H, Holland, Eric C, Pillarisetty, Venu G, Crane, Courtney A
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2020
Matèries:
Immune Cell Therapies and Immune Cell Engineering
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7594542/
https://ncbi.nlm.nih.gov/pubmed/33115946
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001356
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars